Skip to main content

Table 2 Base Case results (ref. Standard care)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy Cost Δ Cost QALY Δ QALY ICER
Standard Care 33369.9   0.7673   
Dexamethasone 33555.6 185.8 0.803 0.0357 5208
Remedesivir 32354.4 -1015.5 0.7734 0.0061 Dominant
Rem + Dex 32540.2 -829.71 0.809 0.0417 Dominant